Pulsenmore

Company Overview

Snapshot

Founded in October 2014 by Elazar Sonnenschein, Pulsenmore operates with 51–200 employees. The company has raised a total of $118.3M across 6 funding rounds from 6 investors. In June 2021, Pulsenmore completed an Initial Public Offering on TASE, raising $40M at a valuation of $190M.

Business overview

Pulsenmore develops a universally accessible home ultrasound device for remote care, enabling patients to self-scan by connecting their smartphone to a handheld ultrasound cradle. The technology primarily focuses on at-home prenatal ultrasound for remote assessment of fetal well-being, empowering women to proactively manage their pregnancies in collaboration with healthcare providers. The company serves the healthcare industry, operating within the Health Tech & Life Sciences sector, with a focus on medical devices, digital healthcare, and patient remote monitoring.

Strategic signal

In November 2025, Pulsenmore received FDA De Novo Marketing Authorization for its home-use prenatal ultrasound device, marking a significant milestone for expanding prenatal care in the U.S. This authorization indicates regulatory validation of the company's innovative technology and signals a new era for remote prenatal monitoring, potentially transforming how expectant mothers receive care and increasing market access for Pulsenmore in a key global market.

Company Intelligence Q&A

What was a significant recent regulatory achievement for Pulsenmore?

In November 2025, Pulsenmore received FDA De Novo Marketing Authorization for its home-use prenatal ultrasound, pioneering a new era of prenatal care in the U.S.

What strategic partnership did Pulsenmore announce in June 2026?

In June 2026, Pulsenmore announced a strategic partnership with Ouma Health to expand access to remote prenatal care across the United States.

When did Pulsenmore commence trading on Nasdaq?

Pulsenmore commenced trading on Nasdaq in January 2026, expanding its FDA-authorized home prenatal ultrasound devices in the U.S.

What was Pulsenmore's first commercial engagement in the U.S. following FDA clearance?

In February 2026, Pulsenmore announced its first commercial engagement with a leading U.S.-Based Medical Center, building U.S. momentum following FDA clearance.

What was a key expansion of Pulsenmore's partnership with Clalit Health Services?

In October 2024, Pulsenmore expanded its partnership with Clalit Health Services to deliver 25,000 home ultrasound devices for remote prenatal care.